Free Trial
→ Please open before June 12! (From InvestPub) (Ad)tc pixel Free NRXPW Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

NRx Pharmaceuticals (NRXPW) Competitors

NRx Pharmaceuticals logo
Compare

NRXPW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy NRx Pharmaceuticals stock or one of its competitors? MarketBeat compares NRx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NRx Pharmaceuticals include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does NRx Pharmaceuticals compare to Ainos?

NRx Pharmaceuticals (NASDAQ:NRXPW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$2.29MN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

In the previous week, Ainos had 2 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 2 mentions for Ainos and 0 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 1.44 beat Ainos' score of 0.93 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
NRx Pharmaceuticals Positive
Ainos Positive

Company Net Margins Return on Equity Return on Assets
NRx PharmaceuticalsN/A N/A N/A
Ainos N/A N/A N/A

Summary

NRx Pharmaceuticals beats Ainos on 2 of the 3 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Alvotech?

NRx Pharmaceuticals (NASDAQ:NRXPW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$2.29MN/AN/AN/AN/A
Alvotech$559.42MN/AN/AN/AN/A

In the previous week, Alvotech had 1 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for NRx Pharmaceuticals. Alvotech's average media sentiment score of 1.89 beat NRx Pharmaceuticals' score of 1.44 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
NRx Pharmaceuticals Positive
Alvotech Very Positive

Company Net Margins Return on Equity Return on Assets
NRx PharmaceuticalsN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats NRx Pharmaceuticals on 3 of the 3 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Aravive?

Aravive (NASDAQ:ARAV) and NRx Pharmaceuticals (NASDAQ:NRXPW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

In the previous week, NRx Pharmaceuticals' average media sentiment score of 1.44 beat Aravive's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
NRx Pharmaceuticals Positive

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
NRx Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
NRx Pharmaceuticals$2.29MN/AN/AN/AN/A

Summary

Aravive and NRx Pharmaceuticals tied by winning 2 of the 4 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and NRx Pharmaceuticals (NASDAQ:NRXPW) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

In the previous week, NRx Pharmaceuticals' average media sentiment score of 1.44 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
NRx Pharmaceuticals Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
NRx Pharmaceuticals$2.29MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
NRx Pharmaceuticals N/A N/A N/A

Summary

NRx Pharmaceuticals beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Biofrontera?

NRx Pharmaceuticals (NASDAQ:NRXPW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, Biofrontera had 1 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for NRx Pharmaceuticals. Biofrontera's average media sentiment score of 1.87 beat NRx Pharmaceuticals' score of 1.44 indicating that Biofrontera is being referred to more favorably in the news media.

Company Overall Sentiment
NRx Pharmaceuticals Positive
Biofrontera Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NRx Pharmaceuticals$2.29MN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
NRx PharmaceuticalsN/A N/A N/A
Biofrontera N/A N/A N/A

Summary

Biofrontera beats NRx Pharmaceuticals on 3 of the 3 factors compared between the two stocks.

Get NRx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRXPW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXPW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRXPW vs. The Competition

Export
MetricNRx PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$453.28M$6.75B$12.02B
Dividend YieldN/A3.86%2.66%5.61%
P/E RatioN/A3.1120.3422.43
Price / SalesN/A6,480.29510.75109.73
Price / CashN/A13.1344.0155.64
Price / BookN/A89.0310.666.79
Net IncomeN/A-$96.07M$3.56B$337.66M

NRx Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRXPW
NRx Pharmaceuticals
N/A$0.00
flat		N/A-97.7%$0.00$2.29MN/AN/A
AIMDW
Ainos
N/A$0.11
-18.2%		N/A+42.1%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.21
-8.7%		N/A-89.1%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NRXPW) was last updated on 6/12/2026 by MarketBeat.com Staff.
From Our Partners
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
There’s a new type of capitalism
The U.S. government has taken direct equity positions in at least 10 companies - Intel, U.S. Steel, Westinghou...
Porter & Company | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
Tesla. SolarCity. Twitter. This $4 stock is next.
Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...
Behind the Markets | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel